Angiology

Branched Stent Grafts Market Size To Reach $477.5 Million By 2028: Grand View Research, Inc.

Medical specialties, Angiology, Cardiovascular system, Vascular diseases, Vascular surgery, Interventional radiology, Thoracic aortic aneurysm, Aneurysm, Aortic aneurysm, Stent, Gustavo S. Oderich, Endovascular aneurysm repair
Wednesday, July 28, 2021 - 9:05am

SAN FRANCISCO, July 28, 2021 /PRNewswire/ -- The global branched stent grafts market size is anticipated to reach USD 477.53 million by 2028, registering a CAGR of 7.9% from 2021 to 2028, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, July 28, 2021 /PRNewswire/ -- The global branched stent grafts market size is anticipated to reach USD 477.53 million by 2028, registering a CAGR of 7.9% from 2021 to 2028, according to a new report by Grand View Research, Inc.
  • In addition, the preference for endovascular treatment for aortic aneurysms further boosts the market growth.
  • Thoracic aortic aneurysm and AAA are types of aortic aneurysms; aneurysms can also occur in other parts of the body.
  • Grand View Research has segmented the global branched stent grafts market on the basis of type, application, and region:
    Branched Stent Grafts Type Outlook (Volume, Units; Revenue, USD Million, 2021 - 2028)
    Branched Stent Grafts Application Outlook (Volume, Units; Revenue, USD Million, 2021 - 2028)

Branched Stent Grafts Market Size To Reach $477.5 Million By 2028: Grand View Research, Inc.

Medical specialties, Angiology, Cardiovascular system, Vascular diseases, Vascular surgery, Interventional radiology, Thoracic aortic aneurysm, Aneurysm, Aortic aneurysm, Stent, Gustavo S. Oderich, Endovascular aneurysm repair
Wednesday, July 28, 2021 - 9:05am

SAN FRANCISCO, July 28, 2021 /PRNewswire/ -- The global branched stent grafts market size is anticipated to reach USD 477.53 million by 2028, registering a CAGR of 7.9% from 2021 to 2028, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, July 28, 2021 /PRNewswire/ -- The global branched stent grafts market size is anticipated to reach USD 477.53 million by 2028, registering a CAGR of 7.9% from 2021 to 2028, according to a new report by Grand View Research, Inc.
  • In addition, the preference for endovascular treatment for aortic aneurysms further boosts the market growth.
  • Thoracic aortic aneurysm and AAA are types of aortic aneurysms; aneurysms can also occur in other parts of the body.
  • Grand View Research has segmented the global branched stent grafts market on the basis of type, application, and region:
    Branched Stent Grafts Type Outlook (Volume, Units; Revenue, USD Million, 2021 - 2028)
    Branched Stent Grafts Application Outlook (Volume, Units; Revenue, USD Million, 2021 - 2028)

ForwardVue Pharma Appoints Bob Katz as Chief Executive Officer

Angiology, Angiogenesis, Macular degeneration, Medical specialties, Organ systems, Clinical medicine
Tuesday, July 27, 2021 - 1:03pm

BOSTON, July 27, 2021 /PRNewswire/ --ForwardVue Pharma names Bob Katz as Chief Executive Officer to advance the pre-clinical development of potent long-acting anti-angiogenic molecules directed against diabetic eye disease and neovascular age related macular degeneration.

Key Points: 
  • BOSTON, July 27, 2021 /PRNewswire/ --ForwardVue Pharma names Bob Katz as Chief Executive Officer to advance the pre-clinical development of potent long-acting anti-angiogenic molecules directed against diabetic eye disease and neovascular age related macular degeneration.
  • Bob Katz is a seasoned life science executive bringing broad, multi-disciplinary expertise in early-stage technology development, clinical applications and successful fundraising.
  • Most recently, Katz was CEO and President of ContraMed where he directed the company from the pre-clinical stage to a successful Phase 3 Clinical Trial and exit.
  • Prior to ContraMed, Katz has held multiple C-level positions at venture-backed startups.

Aurion Biotech Announces IOTA Cell Therapy Trial

Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Optical, Hospitals, Surgery, Genetics, Clinical trials, Health sciences, Life sciences, Medical specialties, Angiology, Endothelium, Therapy
Sunday, July 25, 2021 - 9:00pm

In the IOTA trial, 50 patients diagnosed with corneal endothelial disease were treated with a transformational cell therapy procedure first developed by Professor Shigeru Kinoshita and colleagues at Kyoto Prefecture University of Medicine (KPUM).

Key Points: 
  • In the IOTA trial, 50 patients diagnosed with corneal endothelial disease were treated with a transformational cell therapy procedure first developed by Professor Shigeru Kinoshita and colleagues at Kyoto Prefecture University of Medicine (KPUM).
  • The IOTA trial is the first corneal endothelial cell therapy procedure to be performed successfully outside of Japan, with Drs.
  • The IOTA trial was conducted as a proof of concept of previous studies of the cell therapy procedure developed by Professor Kinoshita and his KPUM colleagues.
  • Aurion Biotech intends to publish key findings in the future, in order to contribute to a greater medical and scientific understanding of corneal endothelial cell therapy.

Stimulating blood vessel formation with magnets

Branches of biology, Biology, Angiology, Stem cells, Growth factors, Vascular endothelial growth factor, Biotechnology, Endothelium, Stromal cell, Mesenchymal stem cell, Cell therapy, Craniofacial regeneration
Wednesday, July 21, 2021 - 11:00pm

This was used to treat endothelial cells, stimulating blood vessel formation.

Key Points: 
  • This was used to treat endothelial cells, stimulating blood vessel formation.
  • "We developed a promising cell therapy alternative that can non-invasively stimulate blood vessel formation or regeneration through the application of an external low-intensity magnetic field."
  • These cells can change into different cell types, and also secrete a protein called VEGF-A that stimulates blood vessel formation.
  • Finally, VEGF-A extracts produced by magnet-treated mesenchymal stromal cells on gelatin increased blood vessel formation in a chick embryo, although further research is needed to confirm these results.

Philips receives FDA Breakthrough Device Designation for laser-assisted IVC filter removal device

Medical specialties, Angiology, Inferior vena cava filter, Interventional radiology, Clinical medicine, Inferior vena cava, IVC, Deep vein thrombosis, Filtration, Filter, Electronic filter, Water filter
Wednesday, July 21, 2021 - 2:00pm

Limited options exist for embedded IVC filter removal, and independent studies indicate high success rates using a Philips excimer laser sheath

Key Points: 
  • Limited options exist for embedded IVC filter removal, and independent studies indicate high success rates using a Philips excimer laser sheath
    Amsterdam, the Netherlands Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the FDA has granted Breakthrough Device Designation (BDD) for a laser-assisted inferior vena cava (IVC) filter removal device.
  • The proposed device is intended for ablating tissue to remove an IVC filter when previous methods of removal have failed.
  • Other identified long-term risks associated with IVC filters include lower limb deep vein thrombosis and IVC occlusion.
  • The failure rate for IVC filter removal is high and limited options for removal exist if the filter has become difficult to remove.

Semler to Report Second Quarter and First Half 2021 Financial Results and Host Conference Call on August 2, 2021

Cardiovascular system, Circulatory system, Cardiovascular physiology, Angiology, Artery, Peripheral artery disease, Conference call
Wednesday, July 21, 2021 - 1:03pm

We encourage participants to pre-register for the conference call using the following link: https://dpregister.com/sreg/10158825/eb5d672fd4 .

Key Points: 
  • We encourage participants to pre-register for the conference call using the following link: https://dpregister.com/sreg/10158825/eb5d672fd4 .
  • Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator.
  • Participants may pre-register at any time, including up to and after the call start time.
  • QuantaFlois a rapid point-of-care test that measures arterial blood flow in the extremities to aid in the diagnosis of peripheral arterial disease.

New Study of a Novel Metabolic Procedure with Self-Assembling Magnets for Obese Patients with Type 2 Diabetes deemed Safe and Feasible

Medical specialties, Clinical medicine, Medicine, Anastomosis, Angiology, Digestive system, Evolutionary biology, Surgery
Tuesday, July 20, 2021 - 3:08pm

The aim of the study was to determine the technical feasibility and safety of sutureless duodeno-ileal side-side anastomosis in obese patients with type 2 diabetes using self-assembling magnets.

Key Points: 
  • The aim of the study was to determine the technical feasibility and safety of sutureless duodeno-ileal side-side anastomosis in obese patients with type 2 diabetes using self-assembling magnets.
  • A dual-path enteral diversion with large-caliber and durable anastomosis was achieved in all patients enrolled in the study.
  • "This publication validates the safety and feasibility for self-assembling magnets and the potential to reshape the landscape in metabolic surgery."
  • In 2020 the FDA granted Breakthrough Therapy designation on GI Window's self-assembling magnets, for a small bowel application.

OncXerna Therapeutics to Present at The LifeSci Partners Private Company Summer Symposium

Branches of biology, Biology, Angiology, Medical specialties, Growth factors, Bayer, Kenilworth, New Jersey, Merck & Co., Schering-Plough, Vascular endothelial growth factor, Angiogenesis inhibitor, Angiogenesis
Monday, July 19, 2021 - 12:00pm

WALTHAM, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc. (OncXerna), a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its first-in-class targeted oncology therapies, today announced that Laura Benjamin, Ph.D., Founder and CEO of OncXerna, will present at the LifeSci Partners Private Company Summer Symposium taking place virtually from July 21-23, 2021.

Key Points: 
  • WALTHAM, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc. (OncXerna), a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its first-in-class targeted oncology therapies, today announced that Laura Benjamin, Ph.D., Founder and CEO of OncXerna, will present at the LifeSci Partners Private Company Summer Symposium taking place virtually from July 21-23, 2021.
  • OncXernas approach pairs those patients with OncXernas clinical-stage therapies and known mechanism of action that directly address these biologies, with the goal to substantially improve patient outcomes.
  • OncXerna is targeting patients whose dominant tumor biology is driven by angiogenesis with a focus beyond VEGF to include broader anti-angiogenic pathways.
  • KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Notal Vision announces publication of first prospective longitudinal pilot study of daily self-imaging with patient-operated Home OCT in wet AMD patients

Branches of biology, Ophthalmology, Clinical medicine, Angiology, Anti–vascular endothelial growth factor therapy, Macular degeneration, Vascular endothelial growth factor
Tuesday, July 13, 2021 - 1:00pm

The study evaluated the ability of subjects to perform sequential daily self-imaging of their eyes with the user-friendly, tele-connected and self-operated Notal Home OCT device in their homes.

Key Points: 
  • The study evaluated the ability of subjects to perform sequential daily self-imaging of their eyes with the user-friendly, tele-connected and self-operated Notal Home OCT device in their homes.
  • Led by Prof. Loewenstein, the pilot study in Israel followed four patients undergoing routine anti-VEGF therapy for wet AMD in one or both eyes for up to three months.
  • Prospective longitudinal pilot study: daily self-imaging with patient-operated home OCT in neovascular age-related macular degeneration.
  • Notal Visions Home OCT system will enable wet AMD patients to perform technician-free OCTtesting at home with rapid and self-guided fixation critical components, especially for elderly patients frequently with pre-existing vision loss.